Remus
Dedicated to Global Healthcare

**Date:** September 02, 2026

To,
The Manager - Listing Department,
**National Stock Exchange of India Limited,**
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

**SYMBOL: REMUS**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting of the Company held on Wednesday, September 02, 2026**

With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Wednesday, September 02, 2026, has inter-alia, approved the following:

1. **Appointment of Mr. Ashutosh Naginbhai Valani (DIN: 00559688) as the Non-Executive Additional Director (Independent Director) of the Company**

   Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Ashutosh Naginbhai Valani (DIN: 00559688) as an Additional (Non- Executive Independent) Director of the Company, not liable to retire by rotation w.e.f. September 02, 2026 and shall hold office till the ensuing Annual General Meeting of the Company.

   The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure- A.**

2. **Migration to Main Board**

   The Board has approved Migration of the securities of the Company from Emerge platform of National Stock Exchange of India Limited to Main Board of National Stock Exchange of India Limited and Main Board of BSE Limited (collectively referred as "Stock Exchanges") as in terms of Chapter IX of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulation, 2018. The proposed migration is subject to the approval of the shareholders of the Company, approval of the Stock Exchanges, and such other approvals, permissions, and consents from regulatory authorities as may be required.

3. **Proposed incorporation of a Subsidiary in Dominican Republic**

   The Board of Directors have accorded their approval for incorporation of a Subsidiary in Dominican Republic to support the Company's business and strategic objectives in Dominican Republic.

   The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure-B**.

Kindly note that the meeting of the Board of Directors of the Company commenced at 04:30 P.M. (IST) and concluded at 05:30 P.M. (IST).

You are requested to take the aforesaid information on your record.

**Thanking you**
**For, Remus Pharmaceuticals Limited**

DEVAL BAKULKUMAR PATEL
Digitally signed by DEVAL BAKULKUMAR PATEL
Date: 2026.09.02 18:07:19 +05'30'

**Deval Patel**
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

**Encls.:** As above

Remus
Dedicated to Global Healthcare

**Annexure -A**

**Appointment of Mr. Ashutosh Naginbhai Valani (DIN: 00559688) as the Non-Executive Additional Director (Independent Director) of the Company**

| Sr. No. | Particulars | Details |
|---|---|---|
| 1. | Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~ | Appointment of Mr. Ashutosh Naginbhai Valani (DIN: 00559688) as the Non-Executive Additional Director (Independent Director) of the Company w.e.f. September 02, 2026. |
| 2. | Date of appointment~~/re-appointment/cessation (as applicable)~~ and-term of appointment | Date of appointment: September 02, 2026<br><br>Term of appointment: Appointed as a Non-Executive Additional Director (Independent Director) for the first term of 5 (Five) consecutive years, not liable to retire by rotation and shall hold office till the ensuing Annual General Meeting of the Company. |
| 3. | Brief Profile (in case of appointment) | Mr. Ashutosh Naginbhai Valani has around 18 years of professional experience and holds professional qualifications from Brunel University, London. He is an entrepreneur, investor and business strategist with extensive experience in the e-commerce, FMCG and Beauty & Personal Care (BPC) sectors.<br><br>He is currently the Co-founder & Director of Renee Cosmetics Private Limited. He previously founded Beardo (Zed Lifestyle Private Limited) and Villain (Villain Lifestyle Private Limited), and has successfully scaled and exited both businesses. He is also an active angel investor in early-stage start-ups.<br><br>Areas of Expertise: Business Strategy, Entrepreneurship, Risk Management, Industry Expertise, Marketing & Brand Management, E-commerce and Business Growth & Scaling.<br><br>He has been recognised in Forbes 30 Under 30 and Fortune 40 Under 40. |
| 4. | Disclosure of relationships between directors (in case of appointment of a director) | Mr. Ashutosh Naginbhai Valani is not related inter-se to any other Directors of Company. |
| 5. | Information as required under BSE circular no. LIST/COMP/14/2018- 19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018 | Mr. Ashutosh Naginbhai Valani is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. |

Remus
Dedicated to Global Healthcare

**Annexure -B**

**Proposed incorporation of a Subsidiary in Dominican Republic**

| **Sr. No.** | **Disclosure Requirement** | **Details** |
|---|---|---|
| 1. | Name of the entity, date & country of incorporation, etc | Name of entity and Date of incorporation: Not applicable as entity is yet to be incorporated<br><br>Proposed country of incorporation: Dominican Republic |
| 2. | Name of holding company of the incorporated company and relation with the listed entity | The entity proposed to be incorporated will be a Subsidiary of Remus Pharmaceuticals Limited ('Company'). |
| 3. | Industry to which the entity being incorporated belongs | Pharmaceutical Industry |
| 4. | Brief background about the entity incorporated in terms of products / line of business | The subsidiary is proposed to be incorporated with the primary objective to undertake the business of supply and distribution of pharmaceutical product in Dominican Republic market and to support the Company's business and strategic objectives in the Dominican Republic. |
| 5. | Brief details of any governmental or regulatory approvals required for the incorporation | As per the regulatory/statutory laws prevailing in Dominican Republic. |
| 6. | Nature of consideration - whether cash consideration or share swap and details of the same | Cash consideration. Company shall subscribe to more than 51% of the initial paid-up share capital of the subsidiary in cash. |
| 7. | Cost of subscription / price at which the shares are subscribed | Not applicable as entity is yet to be incorporated. |
| 8. | Percentage of shareholding / control by the listed entity and / or number of shares allotted | Company will hold 51% or more shareholding of the proposed subsidiary. |

**Remus Pharmaceuticals Limited**
REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857
E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536